Skip to main content
About AtriCure

As a leading provider of innovative technologies for the treatment of Atrial Fibrillation (Afib) and related conditions, electrophysiologists and cardiothoracic surgeons around the globe count on AtriCure to deliver best-in-class solutions that can treat even the most complex cases. Our Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. Our AtriClip Left Atrial Appendage Exclusion System products are the most widely used LAA management devices worldwide. Our Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients, and our cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. We invest in innovation, clinical science, and education to focus on improving lives for our patients worldwide.


We are passionately focused on healing the lives of those affected by Afib and pain after surgery.


We work to heal the lives of Patients, empower our People, and collaborate with our Partners to reduce the burden of Afib worldwide.

AtriCure values Patients, People and Partners

Our first responsibility is to put patients first. We lead rigorous clinical science to determine the safest, most effective approaches and treatments. Our commitment to education generates consistent, predictable practices and standards of care. We undertake relentless innovation to reveal new ideas that improve the experience of providers and supports the care they deliver to each patient.


Our people act with unwavering integrity and transparency in all we do. While honoring the dignity of each person, we foster collaboration to achieve excellence across all areas. We sustain a humble culture of gratitude for each other and the good that we can bring to the world.


We are committed to delivering the highest quality and most efficient solutions to benefit our partners, including care providers, customers, and shareholders. We strive to understand their needs and to offer the products, services, and business value that meet those needs.

Key Facts
  • Served over 575,000 patients with ablation worldwide
  • Over 4,000 healthcare professionals trained
  • Products sold in approximately 60 countries
  • Over 550,000 AtriClip devices sold worldwide
  • 220 issued patents (USA)
  • More than 1,200 employees worldwide
  • Over 450 scientists and engineers
  • Headquartered near Cincinnati, Ohio
  • Developed first and only device approved by FDA for surgical treatment of persistent and long-standing persistent Afib

Our Quality Policy

AtriCure’s quality policy represents its commitment to complying with quality standards and regulations.

AtriCure Quality Policy

Awards and Recognition
Awards and Achievements 2023 2024


Like what you hear? See if an open job opportunity is a fit for me. View Careers